This cross-sectional observational study was conducted to evaluate the implication of CA19-9 level in predicting the extent of hepatic fibrosis in patients with chronic hepatitis B (CHB). Fifty treatment-naive patients with CHB were divided into three groups: group I, patients with no fibrosis (F0; n = 3); group II, patients with mild fibrosis (F1; n = 25) and group III, patients with moderate fibrosis (F3; n = 22). There was no significant (p > 0.05) difference in levels of serum bilirubin, serum alanine aminotransferase, alkaline phosphatase, and alpha fetoprotein among groups I, II and III. Also, mean CA19-9 level did not differ among the three groups. It was observed that, for group II, AUC was 42.6%, sensitivity 52%, specificity 32%, considering cut-off value as 2.8 U/ml to predict F1 liver fibrosis. For group III, AUC was 57.7%, sensitivity 68%, specificity 50% considering cut-off value as 3.2 U/ml to predict F3 fibrosis. The levels of CA19-9 level do not seem to have significant predictive implication to assess hepatic fibrosis.
How to cite this article: Haque MS, Sultana S, Al-Mahtab M, Al-Mamun A, Rahman S. The Value of Serum CA19-9 Levels in predicting Extent of Hepatic Fibrosis in Patients with Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2015;5(1):16-18.
Keywords: CA19-9.; CHB; Liver biopsy.